Clinical trial NCT03129828: Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
Official title: Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the Treatment of Elderly Patients (Age 61-80 Years) With CD20+ Diffuse Large B-cell Lymphoma, IPI ≥ 2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Diffuse Large B Cell Lymphoma
Keywords: Diffuse Large B Cell Lymphoma
Ibrutinib
Bortezomib
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Charite University, Berlin, Germany
name: Janssen-Cilag Ltd.
First posted: 2017-04-26
Enrollment: 38
Sex: ALL
Minimum age (years): 61
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the therapy of higher-risk DLBCL patients of different molecular subtypes and to correlate outcome with clinical, molecular and imaging-guided response parameters. The protocol includes a safety run-in phase, i.e. the phase I part of the study, to uncover unexpected toxicities that may arise in the context of Ibrutinib and Bortezomib co-administered with the R-CHOP backbone. The safety run-in phase is followed by the phase II part of the trial. About 34 patients will be included. Additional 8-11 German university centers and 1-5 in Austria will participate in this trial. The study treatment includes a pre-phase therapy with Prednisone and 6 cycles of a combined immuno-chemotherapy with the anti-CD20 antibody Rituximab together with 6 cycles of a chemotherapy consisting of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone plus Bortezomib and Ibrutinib followed by two additional 3-week cycles of Rituximab. Secondary endpoints are the predictive power of subtypes (such as GCB/ABC-"cell-of-origin"), markers of minimal residual disease over time and during-the-study-determined markers (e.g. gene signatures) to identify patients who benefit from this treatment addition.

Detailed description: Cycle 1 (C1): At C1/day d2, there will be a CT- or ultrasound-guided re-biopsy of a lymphoma lesion that is accessible for biopsy without considerable risk for the patient.

Cycle 2 (C2): After C2, a post-Interim CT will be performed (eventually FDG and FLT PET-CT imaging added to the protocol by amendment).

Cycle 3 (C3): At C3/d0 (prior to therapy), there will also be another bone marrow aspirate for MRD follow-up. At C3/d2, there will be a re-biopsy of a lymphoma site in case of a residual lesion by CT that is accessible for biopsy without considerable risk for the patient. Biopsies can be obtained CT- or ultrasound-guided.

End of treatment/post-therapy: The end-of-treatment visit is required for all subjects, irrespective of a completion of all 8 cycles of therapy or exit of the study protocol. It has to be scheduled approximately 4 to 6 weeks after the last cycle. A total of 7 Follow up visits is planned over 30 months of follow up.

Eligibility criteria: Inclusion Criteria:

* Written informed consent indicating that they understand the purpose of and procedures required for the study, including biomarkers and are willing to participate in the study
* Age ≥ 61 years and ≤ 80 years
* CD20-positive diffuse large B-cell lymphoma (DLBCL); including T-cell-rich large B-cell lymphoma, anaplastic large B-cell lymphoma, plasmablastic lymphoma; follicular lymphoma grade 3b or primary transformed follicular lymphoma at initial diagnosis or highgrade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or high-grade B-cell lymphoma NOS
* Lymphoma biopsy native, fresh-frozen for genome-wide transcriptome array or RNA-Seq analyses (gene expression profiling \[GEP\]) for molecular subtype diagnosis
* Willingness to consent to a re-biopsy in C1/day d2, and - in case of a residual lesion by interim CT - in C3/d2 if it can be obtained without inadequate risk
* Unfavorable risk profile according to the IPI score (IPI ≥ 2)
* Performance status (ECOG) 0-2
* Bi-dimensionally measurable disease (measurable by CT scan or MRI)
* Cardiac ejection fraction ≥ 50 % without clinically significant abnormalities
* Adequate hematological function: hemoglobin ≥ 9 g/dL absolute neutrophil count ≥ 1,00/μL independent of growth factor support and platelet count ≥ 100,000/μL or ≥ 50,000/μL if bone marrow involvement independent of transfusion support in either situation
* Adequate renal function as documented by serum creatinine level \< 2 x ULN or estimated GFR ≥ 40 ml/min/1,73m²
* Adequate hepatic function (total bilirubin ≤ 1,5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, alanine aminotransferase ALT and aspartate aminotransferase AST ≤ 3 x ULN)
* Life expectancy \> 6 months
* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \[ß-hCG\]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study.
* Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, These restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 month after the last dose of study drug.

Exclusion Criteria:

* Unable to sign informed consent
* Secondary transformed B-NHL or types of NHL other than DLBCL and its subtypes according to WHO classification
* Prior therapy for DLBCL
* Known central nervous system lymphoma
* CNS involvement by lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks prior to study entrance) in case of clinical suspicion of CNS involvement by lymphoma
* Major surgery within 4 weeks of study entrance
* History of stroke or intracranial hemorrhage within 6 months prior to study entrance
* Anticoagulation with Warfarin or equivalent vitamin K antagonists (e.g, Phenprocoumon)
* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months of Screening or any class 3 or 4 cardiac disease as defined by NYHA
* treatment with strong CYP3A inhibitors
* Known history of human immunodeficiency virus HIV or active Hepatitis C virus or active Hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous iv antibiotics
* Vaccination with live, attenuated vaccines within 3 weeks of study entrance
* History of solid organ transplantation
* Pregnant or nursing females
* Prior malignancy (except adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, cervical cancer in situ, or any other cancer for which the patient has been in remission for at least 5 years)
* Known hypersensitivity or contraindication to any of the study drugs, its ingredients or recombinant human antibodies and contrast agents
* Pre-existing polyneuropathy of any kind \> grade I
* Severe chronic obstructive pulmonary disease with hypoxemia
* Current or recent (within the last 30 days prior to enrollment) treatment with another investigational drug or participation in another clinical trial
* Evidence of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or patient at high risk from treatment complications
* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules or put the study outcomes at undue risk
* Any co-existing medical or psychological condition that would compromise the ability to give informed consent
* Subjects who are legally detained in an official institution
* Subjects who may be dependent on the sponsor, the investigator or the trial sites, have to be exclude from the trial
* Lack of willingness to storage and disclosure of pseudonymous disease data in the context of the clinical trial

Primary outcomes:
measure: 2-year progression-free survival
timeFrame: 2 years after completion of treatment
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: through study completion, an average of 3 years
measure: 1y- and 2y-PFS for patients based on cell-of-origin (COO, i.e. GCB vs. ABC subtype)
timeFrame: 1 and 2 years after end of treatment
measure: number of patients with complete remission in all patients and based on cell-of-origin
timeFrame: 2 years after end of treatment
measure: Predictive power of markers for Minimal Residual Disease (MRD) over time
timeFrame: 2 years after end of treatment
measure: Objective Response Rate (ORR) in all patients and based on cell-of-origin
timeFrame: 2 years after end of treatment
measure: Disease-Free Survival in all patients and based on cell-of-origin
timeFrame: 2 years after end of treatment
measure: Overall survival in all patients and based on cell-of-origin
timeFrame: 2 years after end of treatment
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum
Study officials:
affiliation: Representative of the Sponsor, National Coordinator, Principal Investigator
name: Clemens Schmitt, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Denker S, Bittner A, Na IK, Kase J, Frick M, Anagnostopoulos I, Hummel M, Schmitt CA. A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-kappaB-double-targeting to molecularly assess therapy response. Int J Hematol Oncol. 2019 Dec 19;8(4):IJH20. doi: 10.2217/ijh-2019-0010.